Company Analysis
Sign in

Immunome, Inc. (IMNM)

Nasdaq: IMNM · Pharmaceutical Preparations · Bothell, WA · filing with the SEC since 2009
Full chart Alerts Compare
Grade5.1
◀ Past 3.2● Present 5.0▶ Future 6.5
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

10 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Immunome, Inc.’s names, not what it holds today.

Patents granted
10
10 utility, 1976 to Dec 31, 2025
Granted in 2025
8
Against 1 in 2024 and 1 in 2023
Applications published
11
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals8
Biotechnology1
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Immunome, Inc. its own name
US, as the owner printed on each patent
10 granted
2 published
Immunome, Inc. its own name
named as the applicant on its applications, in US
0 granted
9 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 23, 202512,503,449Methods of preparing chiral benzodiazepinone derivativesOrganic fine chemistryImmunome, Inc.
Apr 29, 202512,285,492Immunoconjugates and methodsPharmaceuticalsImmunome, Inc.
Apr 22, 202512,281,085Bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereofPharmaceuticalsImmunome, Inc.
Apr 22, 202512,280,121Immunoconjugates and methodsPharmaceuticalsImmunome, Inc.
Apr 15, 202512,274,754Immunoconjugates and methodsPharmaceuticalsImmunome, Inc.
Apr 8, 202512,268,750Immunoconjugates and methodsPharmaceuticalsImmunome, Inc.
Feb 25, 202512,233,072Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating Adenoid Cystic CarcinomaPharmaceuticalsImmunome, Inc.
Jan 7, 202512,186,403Immunoconjugates and methodsPharmaceuticalsImmunome, Inc.
Dec 10, 202412,162,945EPHA2 antibodiesPharmaceuticalsImmunome, Inc.
Dec 5, 202311,834,493Antibody cocktail against SARS-CoV-2 spike proteinBiotechnologyImmunome, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 13, 20252025/0346565METHODS OF PREPARING CHIRAL BENZODIAZEPINONE DERIVATIVESOrganic fine chemistryImmunome, Inc.
Sep 4, 20252025/0276077EPHA2 ANTIBODIESPharmaceuticalsImmunome, Inc.
Feb 13, 20252025/0051464EPHA2 ANTIBODIESPharmaceuticalsImmunome, Inc.
Sep 26, 20242024/0316062COMBINATION OF IMMUNOTHERAPEUTICS AND BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR TREATING CANCERPharmaceuticalsImmunome, Inc.
May 30, 20242024/0174741IL-38-SPECIFIC ANTIBODIESPharmaceuticalsImmunome, Inc.
Feb 29, 20242024/0067704ANTIBODY COCKTAIL AGAINST SARS-COV-2 SPIKE PROTEINBiotechnologyImmunome, Inc.
Sep 1, 20222022/0275077IL-38-SPECIFIC ANTIBODIESPharmaceuticalsImmunome, Inc.
Jul 28, 20222022/0235118ANTIBODY COCKTAIL AGAINST SARS-COV-2 SPIKE PROTEINBiotechnologyImmunome, Inc. · patent 11,834,493 granted from it
Jan 6, 20222022/0002435ANTIBODIES TARGETING EPN1BiotechnologyImmunome, Inc.
Nov 11, 20212021/0347895EXOSOME-TARGETING BISPECIFIC ANTIBODIESBiotechnologyImmunome, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 4 · Biotechnology 1 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton IMNM · research, not advice